Lupus nephritis with corticosteroid responsiveness : molecular changes of CD46-mediated type 1 regulatory T cells
© 2021. The Author(s), under exclusive licence to the International Pediatric Research Foundation, Inc..
BACKGROUND: The engagement of the complement regulatory proteins CD46 and CD3 in human CD4+ T cells induces the type 1 regulatory T cells (Tr1) and interleukin-10 (IL-10) secretion. This study aimed to elucidate the molecular changes of Tr1 cells through CD46 cytoplasmic Cyt1 tail in lupus nephritis (LN) respond to intravenous methylprednisolone (ivMP) therapy.
METHODS: We enrolled 40 pediatric patients with LN and 30 healthy controls. Clinical characteristics and peripheral blood mononuclear cells were collected before and 3 days after the administration of ivMP. Kidney specimens were taken from five LN and five minimal-change nephrotic syndrome patients.
RESULTS: We found that defective CD46-mediated T-helper type 1 contraction (IL-10 switching) is present in active LN patients. The ivMP therapy enhanced LN remission, restored the production of IL-10, increased the CD46-Cyt1/Cyt2 ratio, AKT, and cAMP-responsive element-binding protein phosphorylation, and induced migration with the expression of chemokine receptor molecules CCR4, CCR6, and CCR7 of CD3/CD46-activated Tr1 cells.
CONCLUSIONS: Pharmacologic interventions that alter the patterns of CD46-Cyt1/Cyt2 expression and the secretion of IL-10 by CD3/CD46-activated Tr1 cells can be used in patients with active LN.
IMPACT: In patients with LN, ivMP was associated with increased IL-10 production and increased CD46-Cyt1/Cyt2 ratio and AKT phosphorylation by Tr1 cells, with enhanced potential to migration in response to CCL17. These results suggest that expression levels of CD46 isoforms Cyt1 and Cyt2 in CD4 + CD46 + Tr1 cells differ in patients with active LN but can be corrected by corticosteroid treatment. Enhancing the expression of functional CD4 + CD46 + Tr1 cells may be a useful therapeutic approach for LN.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:92 |
---|---|
Enthalten in: |
Pediatric research - 92(2022), 4 vom: 24. Okt., Seite 1099-1107 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Tsai, Yi-Giien [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 25.10.2022 Date Revised 21.12.2022 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1038/s41390-021-01882-z |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM334888360 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM334888360 | ||
003 | DE-627 | ||
005 | 20231225224650.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1038/s41390-021-01882-z |2 doi | |
028 | 5 | 2 | |a pubmed24n1116.xml |
035 | |a (DE-627)NLM334888360 | ||
035 | |a (NLM)34952938 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Tsai, Yi-Giien |e verfasserin |4 aut | |
245 | 1 | 0 | |a Lupus nephritis with corticosteroid responsiveness |b molecular changes of CD46-mediated type 1 regulatory T cells |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 25.10.2022 | ||
500 | |a Date Revised 21.12.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2021. The Author(s), under exclusive licence to the International Pediatric Research Foundation, Inc. | ||
520 | |a BACKGROUND: The engagement of the complement regulatory proteins CD46 and CD3 in human CD4+ T cells induces the type 1 regulatory T cells (Tr1) and interleukin-10 (IL-10) secretion. This study aimed to elucidate the molecular changes of Tr1 cells through CD46 cytoplasmic Cyt1 tail in lupus nephritis (LN) respond to intravenous methylprednisolone (ivMP) therapy | ||
520 | |a METHODS: We enrolled 40 pediatric patients with LN and 30 healthy controls. Clinical characteristics and peripheral blood mononuclear cells were collected before and 3 days after the administration of ivMP. Kidney specimens were taken from five LN and five minimal-change nephrotic syndrome patients | ||
520 | |a RESULTS: We found that defective CD46-mediated T-helper type 1 contraction (IL-10 switching) is present in active LN patients. The ivMP therapy enhanced LN remission, restored the production of IL-10, increased the CD46-Cyt1/Cyt2 ratio, AKT, and cAMP-responsive element-binding protein phosphorylation, and induced migration with the expression of chemokine receptor molecules CCR4, CCR6, and CCR7 of CD3/CD46-activated Tr1 cells | ||
520 | |a CONCLUSIONS: Pharmacologic interventions that alter the patterns of CD46-Cyt1/Cyt2 expression and the secretion of IL-10 by CD3/CD46-activated Tr1 cells can be used in patients with active LN | ||
520 | |a IMPACT: In patients with LN, ivMP was associated with increased IL-10 production and increased CD46-Cyt1/Cyt2 ratio and AKT phosphorylation by Tr1 cells, with enhanced potential to migration in response to CCL17. These results suggest that expression levels of CD46 isoforms Cyt1 and Cyt2 in CD4 + CD46 + Tr1 cells differ in patients with active LN but can be corrected by corticosteroid treatment. Enhancing the expression of functional CD4 + CD46 + Tr1 cells may be a useful therapeutic approach for LN | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a Interleukin-10 |2 NLM | |
650 | 7 | |a 130068-27-8 |2 NLM | |
650 | 7 | |a Membrane Cofactor Protein |2 NLM | |
650 | 7 | |a Receptors, CCR7 |2 NLM | |
650 | 7 | |a Proto-Oncogene Proteins c-akt |2 NLM | |
650 | 7 | |a EC 2.7.11.1 |2 NLM | |
650 | 7 | |a Methylprednisolone |2 NLM | |
650 | 7 | |a X4W7ZR7023 |2 NLM | |
650 | 7 | |a Protein Isoforms |2 NLM | |
650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
650 | 7 | |a CD46 protein, human |2 NLM | |
700 | 1 | |a Chien, Jien-Wen |e verfasserin |4 aut | |
700 | 1 | |a Chiu, Ying-Ming |e verfasserin |4 aut | |
700 | 1 | |a Su, Tzu-Cheng |e verfasserin |4 aut | |
700 | 1 | |a Chiu, Ping-Fang |e verfasserin |4 aut | |
700 | 1 | |a Hsiao, Kai-Hung |e verfasserin |4 aut | |
700 | 1 | |a Lin, Ching-Yuang |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Pediatric research |d 1967 |g 92(2022), 4 vom: 24. Okt., Seite 1099-1107 |w (DE-627)NLM000008672 |x 1530-0447 |7 nnns |
773 | 1 | 8 | |g volume:92 |g year:2022 |g number:4 |g day:24 |g month:10 |g pages:1099-1107 |
856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41390-021-01882-z |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 92 |j 2022 |e 4 |b 24 |c 10 |h 1099-1107 |